2 news items
Cogent Biosciences Announces Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis; 51% Week 12 Mean Change In Total Symptom Score, Including 70% Of Patients Achieving ≥50% Reduction In TSS At Week 12
COGT
22 Feb 24
that we have initiated SUMMIT Part 2, with extremely positive support from the NonAdvSM community," said Andrew Robbins, Cogent's President and Chief
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
COGT
22 Feb 24
the NonAdvSM community," said Andrew Robbins, Cogent's President and Chief Executive Officer. "The magnitude and speed of symptomatic reductions, along
- Prev
- 1
- Next